T cell receptor alpha variable 24Genealiases: TCRAV18S1 · TCRAV24S1
Q-omics provides the consensus-scored TRAV24 profile across patient tissues and cancer cell-line models. TRAV24 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAV24 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TRAV24 RNA expression shows 12,797 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where TRAV24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV24 survival associations across molecular data types. TRAV24 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV24 RNA expression–survival associations across cancer types. High TRAV24 expression shows favorable associations in SKCM, BRCA, HNSC, BLCA, OV and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAV24 RNA expression.
This table summarizes TRAV24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV24 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher TRAV24 RNA expression in tumor versus normal tissue (log2 FC = +0.975, t-test p < 0.001).
This table shows molecular features associated with TRAV24 in patient tissues and cancer cell lines. In patient samples, TRAV24 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
